New combo therapy may shield diabetic kidneys from damage
NCT ID NCT07586371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an SGLT2 inhibitor to standard ARB therapy better reduces protein in the urine (a sign of kidney damage) in diabetic patients without high blood pressure. Sixty adults aged 30-60 with diabetes and microalbuminuria will receive either ARBs alone or ARBs plus an SGLT2 inhibitor. The goal is to see which approach more effectively lowers proteinuria and slows kidney disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faisalabad Medical University
Faisalābad, Punjab Province, Pakistan